Belamaf Regimen Improves Progression-Free Survival in Myeloma

Belamaf plus bortezomib and dexamethasone lengthened the time patients with relapsed or refractory myeloma lived before their disease got worse.

Related Keywords

United States ,American , ,American Society Of Clinical Oncology Annual Meeting ,Clinical Oncology Annual ,Thenew England Journal ,Victoria Mateos ,Hospital Universitario De Salamanca ,Instituto De Investigaci ,Centro De Investigaci ,